260 related articles for article (PubMed ID: 17877516)
1. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
[No Abstract] [Full Text] [Related]
2. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
Corominas H; Díaz C; Vázquez G; Baiget M
Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
[No Abstract] [Full Text] [Related]
3. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.
Winter J; Walker A; Shapiro D; Gaffney D; Spooner RJ; Mills PR
Aliment Pharmacol Ther; 2004 Sep; 20(6):593-9. PubMed ID: 15352906
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
7. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
8. The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation.
Fabre MA; Jones DC; Bunce M; Morris PJ; Friend PJ; Welsh KI; Marshall SE
Transpl Int; 2004 Oct; 17(9):531-9. PubMed ID: 15349717
[TBL] [Abstract][Full Text] [Related]
9. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
10. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Shah JA; Edwards CM; Probert CS
Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):169-73. PubMed ID: 18301295
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
12. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
Campbell S; Kingstone K; Ghosh S
Aliment Pharmacol Ther; 2002 Mar; 16(3):389-98. PubMed ID: 11876691
[TBL] [Abstract][Full Text] [Related]
13. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.
van Dieren JM; van Vuuren AJ; Kusters JG; Nieuwenhuis EE; Kuipers EJ; van der Woude CJ
Gut; 2005 Nov; 54(11):1664. PubMed ID: 16227370
[No Abstract] [Full Text] [Related]
14. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab M; Herrlinger K; Schaeffeler E; Stange EF
Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
[No Abstract] [Full Text] [Related]
16. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
17. Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients.
Derijks LJ; van Helden RB; Hommes DW; Stokkers PC
Gut; 2008 Jun; 57(6):872. PubMed ID: 18477684
[No Abstract] [Full Text] [Related]
18. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.
Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J
Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518
[TBL] [Abstract][Full Text] [Related]
20. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
